​

Veradermics (MANE) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

MANE Stock Forecast

Veradermics (MANE) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $162.67, with a high of $182.00 and a low of $136.00. This represents a 66.11% increase from the last price of $97.93.

MANE Stock Rating

Veradermics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

MANE Price Target Upside V Benchmarks

TypeNameUpside
StockVeradermics66.11%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-34
Avg Price Target-$162.67$140.75
Last Closing Price$97.93$97.93$97.93
Upside/Downside-66.11%43.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 2616---7
Jul, 2615---6
Jun, 26-4---4
May, 26-4---4
Apr, 26-4---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 15, 2026UBS$170.00$110.1754.31%73.59%
Jul 07, 2026Jefferies$182.00$119.0552.88%85.85%
Jun 02, 2026Needham$136.00$101.5133.98%38.87%
Mar 02, 2026Roger SongJefferies$75.00$45.8563.58%-23.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 16, 2026CitigroupBuyBuyhold
Jul 15, 2026B. RileyBuyinitialise
Jul 07, 2026JefferiesBuyBuyhold
Jun 02, 2026NeedhamBuyinitialise
May 18, 2026CitigroupBuyBuyhold
Apr 27, 2026CitigroupBuyBuyhold
Mar 02, 2026CitigroupBuyinitialise
Mar 02, 2026Cantor FitzgeraldOverweightinitialise
Mar 02, 2026JefferiesBuyinitialise

Financial Forecast

EPS Forecast

Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-0.09$-2.10
High Forecast$-0.09$-2.10
Low Forecast$-0.09$-2.10
Surprise %--

Revenue Forecast

Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-450M $-360M $-270M $-180M $-90M $0 Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-18.12M$-422.80M
High Forecast$-18.12M$-422.80M
Low Forecast$-18.12M$-422.80M
Surprise %--

MANE Forecast FAQ

Is Veradermics stock a buy?

Veradermics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Veradermics is a favorable investment for most analysts.

What is Veradermics's price target?

Veradermics's price target, set by 4 Wall Street analysts, averages $162.67 over the next 12 months. The price target range spans from $136 at the low end to $182 at the high end, suggesting a potential 66.11% change from the previous closing price of $97.93.

How does Veradermics stock forecast compare to its benchmarks?

Veradermics's stock forecast shows a 66.11% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Veradermics over the past three months?

  • August 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Veradermics’s EPS forecast?

Veradermics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.09, marking a 0% decrease from the reported - in 2024. Estimates for the following years are.

What is Veradermics’s revenue forecast?

Veradermics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for.

What is Veradermics’s net income forecast?

Veradermics's net income forecast for the fiscal year ending in December 2025 stands at $-18.12M, representing a 0% decrease from the reported - in 2024. Projections indicate .